Two of the world's top 500 pharmaceutical giants have come under fire for their "snake swallowing elephant" mergers and acquisitions.

Recently, the 2020 Fortune 500 list has been published.
In terms of the list, there are 13 pharmaceutical companies in the pharmaceutical industry, including three Chinese pharmaceutical companies, China Resources (79th), China Pharmaceutical Group (145th) and Shanghai Pharmaceuticals (473rd).
Johnson and Johnson remain in the top two for multinational pharmaceutical companies this time, but the third place is held by Bayer, replacing the original Pfizer position (Pfizer is currently down 17 places).
it is worth mentioning that the members of this new pharmaceutical industry include Takeda and Shishi Shiguibao, of which Takeda is the first time into the top 500, Andshi Shiguibao is a decade later to return to the top 500.
2020 list, Takeda ranks 414th in the world with $30,272 million in revenue, while Shishi Shiguibao ranks 487th with $26.145 billion in revenue.
industry believes that the two pharmaceutical companies can successfully launch the world's top 500 this time, and its behind the merger and acquisition action has something to do.
2019, Takeda and Shishi Shiguibao launched a major acquisition known to the industry.
, Takeda announced in January 2019 that it would complete its $62 billion acquisition of Shire, a biopharmaceutical company that develops and produces drugs for rare diseases.
Through this acquisition, Takeda further expanded its research and development pipeline in the field of rare diseases and increased its voice in the rare diseases sector with the rare diseases segment of Shire, achieving an increase of 390.6% year-on-year, making it a very important revenue source.
The acquisition, which brought a 60 per cent increase in Takeda's 2019 revenues, successfully pushed pharmaceutical giants such as AstraZeneta and Amway into the top 10 global pharmaceutical companies, but its 2019 profit fell 58.7 per cent year-on-year to $407m, according to earnings reports.
Centennial completed a $74 billion acquisition of New Base in November 2019, acquiring a number of research and development lines in the fields of tumors, immunity, and inflammation, including the new base's successful cancer drug, Amine.
the merger agreement, Xinji became a wholly owned subsidiary of Shishi Shiguibao Company.
other time, The President of Shishi Shiguibao and CE0 Kang Ruijie said, to the Shishi Shiguibao and Xinji advantages in a variety of ways, together to create a world-leading biopharmaceutical enterprises.
the scale of the acquisition, which also caused a stir in the industry at the time.
acquisition, the company's global revenue exceeded $39.8 billion in 2019, with revenue growth of more than 15%, ranking among the top 10 multinational pharmaceutical companies.
's contribution to profits has yet to be seen.
2019, The Company reported a profit of $3.439 billion, down 30.1% year-on-year.
addition to the pharmaceutical companies mentioned above, roche, Bayer, Novarma, Mercedon, GSK, Sanofi, AbbVie and other multinational pharmaceutical companies are also on the shortlist.
the new ranking of Mercedon changed significantly, rising 29 places to 256.
2019, Mercedon's revenue and profit reached $46.840 billion and $9.843 billion, respectively, up 10.7 and 58.2 percent year-on-year, according to
financial results, which were mainly driven by sales of the company's PD-1 drug Keytruda and 9-price cervical cancer vaccine Gardasil 9, respectively.
keytruda is in the top 20 in Evaluate Pharma's 2019 list of global drug sales.
Evaluate Pharma predicts that Gilled's Bikarvy, the drug with the highest compound annual growth rate, will grow at a compound annual rate of plus 14 percent, followed by Keytruda in Mercedon and Ibrox at a compound annual growth rate of plus 12 percent.
.